Biotech Values

[jb_118]

2Q11 generic Lovenox sales = $284M:

Anybody care to hazard an EPS for MNTA based on this sales figure? I haven't been tracking the pass through to MNTA from gross mEnox sales, but seems like it is about 31% of gross, with about 23M in spend and about 51M outstanding shares, roughs out to $1.28/share. Should bring them up to about $3.88 EPS for the previous 4 quarters, for a trailing PE of ~5. Should end the Q with about $6/share cash and receivables.

It seems like others have modeled this more accurately. Anybody else have something less rough?